BioDelivery Sciences (BDSI) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioDelivery Sciences Provides Corporate Update and Reports Second Quarter 2015 Financial Results
August 10, 2015 7:00 AM EDTRALEIGH, N.C., Aug. 10, 2015 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the second quarter ended June 30, 2015, and reviewed its most significant recent accomplishments and upcoming milestones.
Net revenue for the second quarter ended June 30, 2015, was $1.7 million compared to $13.9 million in the corresponding period of 2014. Revenue for the second quarter versus 2014 is less due to 2014 containing the database lock for one of the BELBUCA Phase 3 trials. Net revenue for BUNAVAIL increased 23% versus first quarter while operating expenses decreased by 10% over the... More
